Please login to the form below

Not currently logged in
Email:
Password:

RCC

This page shows the latest RCC news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on kidney cancer drug

Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on kidney cancer drug

The SMC has approved its use on the NHS as a first-line treatment for people with advanced renal cell carcinoma (RCC), which could enable around 165 eligible patients in a

Latest news

More from news
Approximately 10 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Although marketed as the orphan drug Cometriq for thyroid neoplasms, it’s as Cabometyx in renal cell carcinoma (RCC) where the firm views real potential. ... Approved in Europe as a treatment for advanced RCC, Cabometyx won backing from NICE at its

  • Charting a course for expansion Charting a course for expansion

    I think these is some really game-changing data for first-line and second-line RCC patients.”. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics